Treatment of neurodegenerative diseases

Novel triazinone derivatives and their use as therapeutic agents to treat a variety of neurodegenerative disorders, including Alzheimer’s disease.

Title of the patent Dual inhibitor compounds for the treatment of neurodegenerative disorders and Alzheimer’s disease
Thematic area Pharmaceutical
Ownership Alma Mater Studiorum - Università di Bologna and Fondazione Istituto Italiano di Tecnologia
Inventors Andrea Cavalli, Maria Laura Bolognesi, Federica Prati, Giovanni Bottegoni, Angelo Danilo Favia, Daniela Pizzirani, Rita Scarpelli
Protection International application
Licensing status Available for licensing agreement
Keywords Triazinone, derivatives, neurodegenerative, disorders, Alzheimer’s disease (AD)
Filed on Jun 13, 2013

AD is a progressive neurological disorder characterized by deterioration of cognitive function, dementia, memory loss, and altered behavior. Multitarget drugs (MTDs), namely small organic molecules able to hit multiple targets belonging to different pathological pathways, are emerging as promising disease-modifying compounds for the treatment of complex neurological disorders.

Synthesis of new derivatives of triazinone and their use as therapeutic agents to treat a variety of neurodegenerative disorders, including Alzheimer's disease (AD).

The aim of the present invention is therefore to provide novel compounds having a large spectrum of neuroprotective and anti-neurodegenerative properties and able to be effective in the treatment of AD. In particular, one of the aim of the present invention is to provide novel compounds having inhibitory activity against BACE-1 and GSK-3β demonstrating an increased neuroprotective and neurogenesis activity to treat Alzheimer’s disease.

  • Simplified therapeutic regimen
  • Improved compliance
  • Improved efficacy due to the synergistic effect of simultaneously inhibiting multiple targets
  • Improved safety by decreasing the side effects related to the load of a drug cocktail